Key Points
- Insider sale: Adaptive Biotechnologies Chief Scientific Officer Harlan Robins sold 100,000 shares at an average price of $17.37, totaling $1.737 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- Stock and earnings backdrop: ADPT was trading down 2.6% at $16.78, with shares ranging from a 52-week low of $9.96 to a high of $20.76. The company recently reported a smaller-than-expected loss and revenue that beat estimates, with year-over-year revenue growth of 35.1%.
- Funding and analyst outlook: The company upsized a convertible note offering to $300 million and plans to use proceeds for debt repayment, capped-call protection, and a $25 million buyback to offset dilution. Despite mixed views, BTIG reiterated a Buy rating with a $22 price target, while the consensus remains Moderate Buy.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) insider Harlan Robins sold 6,160 shares of the firm's stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $18.01, for a total value of $110,941.60. Following the completion of the sale, the insider directly owned 1,405,898 shares of the company's stock, valued at approximately $25,320,222.98. This trade represents a 0.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Adaptive Biotechnologies Stock Down 2.6%
Shares of Adaptive Biotechnologies stock opened at $16.78 on Thursday. The stock has a market cap of $2.69 billion, a PE ratio of -50.85 and a beta of 2.15. The business has a fifty day simple moving average of $14.72 and a 200-day simple moving average of $15.59. Adaptive Biotechnologies Corporation has a 12 month low of $9.96 and a 12 month high of $20.76.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. The business had revenue of $70.87 million during the quarter, compared to analysts' expectations of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.Adaptive Biotechnologies's revenue was up 35.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.20) earnings per share. Analysts expect that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current fiscal year.
Hedge Funds Weigh In On Adaptive Biotechnologies
Several institutional investors have recently bought and sold shares of ADPT. Westfield Capital Management Co. LP bought a new position in Adaptive Biotechnologies during the fourth quarter valued at about $65,942,000. Price T Rowe Associates Inc. MD raised its holdings in Adaptive Biotechnologies by 303.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company's stock valued at $71,252,000 after buying an additional 3,299,635 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in Adaptive Biotechnologies by 84.3% during the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company's stock valued at $89,337,000 after buying an additional 2,731,648 shares in the last quarter. Invesco Ltd. raised its holdings in Adaptive Biotechnologies by 248.8% during the fourth quarter. Invesco Ltd. now owns 3,107,653 shares of the company's stock valued at $50,468,000 after buying an additional 2,216,595 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its holdings in Adaptive Biotechnologies by 544.0% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company's stock valued at $36,523,000 after buying an additional 2,062,282 shares in the last quarter. 99.17% of the stock is currently owned by institutional investors.
Key Headlines Impacting Adaptive Biotechnologies
Here are the key news stories impacting Adaptive Biotechnologies this week:
- Positive Sentiment: BTIG Research reaffirmed its Buy rating on Adaptive Biotechnologies and set a $22 price target, implying meaningful upside from recent trading levels.
- Positive Sentiment: The company priced an upsized $300 million offering of 0% convertible senior notes due 2031, and management said proceeds will help repay the OrbiMed agreement, fund capped-call protection, and support a $25 million share repurchase to reduce dilution.
- Neutral Sentiment: The initial conversion price of about $24.11 per share and capped-call structure may help limit dilution if the stock rises, which could support longer-term sentiment.
- Negative Sentiment: Investors may view the larger convertible issuance as a sign of financing needs, especially since the offering was increased from $250 million to $300 million.
- Negative Sentiment: Insider selling added pressure: Chief Scientific Officer Harlan S. Robins sold 106,160 shares in two recent transactions, and the company’s recent insider activity has consisted entirely of sales.
- Negative Sentiment: A prior report also noted the stock fell after the original convertible-debt plan, suggesting shareholders are sensitive to dilution and capital-structure changes.
Analysts Set New Price Targets
ADPT has been the subject of a number of research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Morgan Stanley reduced their price objective on Adaptive Biotechnologies from $21.00 to $18.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 12th. BTIG Research reissued a "buy" rating and set a $22.00 price objective on shares of Adaptive Biotechnologies in a research report on Wednesday. TD Cowen lifted their price objective on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a "buy" rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen cut Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a research report on Saturday, March 7th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $20.33.
Check Out Our Latest Stock Report on Adaptive Biotechnologies
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
